Hairy cell leukemia (HCL) is characterized by a severe T-cellmediated immune deficiency. At the same time, spontaneous T-cell activation is noted when splenic T cells are studied in vivo and in vitro. Therefore, we searched for oligoclonal T-cell populations in the blood and spleens of 25 patients with HCL using a T-cell receptor y-polymerase chain reaction (TCRyPCR). Subsequently, in 6 patients, the CDR3 length and conformation from 22 different TCRBV subfamilies were analyzed after PCR amplification of cDNA using TCRBV subfamily-specific primers. T cells from 15 of 25 HCL patients showed clonal excess by the TCRy-PCR. In fluorescence-activated cell sorted T-cell subsets, more clonal bands were observed than in the unseparated T cells, with most of these in CD8' subsets, but also in CD4+. CD3+yIS+. and a double-negative CD3+a/j?+ subset. In other B-cell malignancies, 6 of 16 samples showed oligoclonal T cells, whereas AIRY CELL leukemia (HCL) is a chronic B-cell leuke-
Hairy cell leukemia (HCL) is characterized by a severe T-cellmediated immune deficiency. At the same time, spontaneous T-cell activation is noted when splenic T cells are studied in vivo and in vitro. Therefore, we searched for oligoclonal T-cell populations in the blood and spleens of 25 patients with HCL using a T-cell receptor y-polymerase chain reaction (TCRyPCR). Subsequently, in 6 patients, the CDR3 length and conformation from 22 different TCRBV subfamilies were analyzed after PCR amplification of cDNA using TCRBV subfamily-specific primers. T cells from 15 of 25 HCL patients showed clonal excess by the TCRy-PCR. In fluorescence-activated cell sorted T-cell subsets, more clonal bands were observed than in the unseparated T cells, with most of these in CD8' subsets, but also in CD4+. CD3+yIS+. and a double-negative CD3+a/j?+ subset. In other B-cell malignancies, 6 of 16 samples showed oligoclonal T cells, whereas AIRY CELL leukemia (HCL) is a chronic B-cell leuke-H mia characterized by pancytopenia and splenomegaly with clonal expansion of malignant mature B cells in the spleen, bone marrow, and blood. Characteristically, patients with HCL do not suffer from the leukemia itself but from accompanying symptoms related to the disease, such as the pancytopenia and severe opportunistic infections.'.' Although HCL is a B-cell malignancy, many observations argue for a T-cell dysfunction and/or involvement. Among these are, in addition to the above-mentioned severe infections, defective K, natural killer (NK), and lymphokine-activated killer (LAK) cell f~nctions~.~; a remarkable decrease in the percentage and number of circulating memory Thelper cells (CD4'CD45ROC)5; a reversed CD4/CD8 ratio with an increase in CD3+TCRyISC cells in the spleen6; extreme sensitivity to interferon-a (IFN-c~)~; and abnormal proliferative responses of autologous or allogeneic T cells to hairy cells. 8 Hairy cells typically home to the spleen and circulate only late in the disease. It is assumed that the T-cell abnormalities are caused by specific interactions with the hairy cells. Without specific induction, spontaneous cytokine gene expression of interleukin-2 (IL-2), IL-4, IFN-y , and granulocyte-macrophage colony-stimulating factor (GM-CSF) was seen in splenic purified T-cell fractions without signals in the purified hairy cell fractions6
If the presence of activated T cells in the spleen is related to cellular immunity against the malignant cells, one would expect to find predominant clones as the result of a (oligo)clonal involvement of the T cells.' The combination of spontaneous T-cell activation, decreased numbers of memory T cells, and opportunistic infections may also be due to inappropriate activation and suppression of T-cell responses by the hairy cells, resulting in a restricted T-cell repertoire. Oligoclonality and a limitation of the T-cell repertoire can be studied by the analysis of rearrangement patterns of Tcell receptor (TCR) and TCRy genes. The y chain locus is rearranged in all T-cell subsets" and consists of a limited V and J gene repertoire, but an extensive junctional diversity,lo." that can be amplified by a polymerase chain reaction only 2 of 18 normal spleen and blood samples showed abnormal bands. Analysis of the TCRBV subfamilies disclosed in all 6 HCL patients a markedly abnormal pattern, with many clonal bands in 5 t o 15 subfamilies, and absent or abnormal weak patterns in another 1 t o 8 subfamilies. In comparison, 6 normal samples (2 spleens and 4 blood samples) showed in only 1 blood donor 1 clonal band. Two patients with active HCL but without infections or treatment were tested several times during the course of the disease and showed a complete identical skewed T-cell repertoire with the same oligoclonal T-cell populations. In conclusion, T cells in the blood and spleen of HCL patients show impressive abnormalities with many oligoclonal T-cell populations and a very restricted and skewed TCRBV repertoire.
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(PCR) and analyzed by the length of the junction site. This is a rapid and specific screening method for the detection of oligoclonality of T cells without the need for Southern blotting." A more detailed but much more laborious analysis can be performed by studying TCRBV patterns, which can be performed by amplifying reversed-transcribed mRNA using oligonucleotide primers specific for almost all BV subfamilies. We selected both techniques to study splenic and circulating T cells in HCL. A high incidence of oligoclonal T-cell populations was found with an impressively restricted and skewed TCRBV repertoire. Furthermore, data on a limited number of patients illustrate persistence of these abnormalities during follow-up.
MATERIALS AND METHODS

Cell Lines
T-cell clone (JBI-Bl) were used as controls.
The clonal T-cell line Jurkat and a proliferative alloreactive CD4+
Cell Isolation
Peripheral blood and spleen samples from 25 patients with HCL that were collected during the last decade were studied. The diagnosis was confirmed by histologic analysis of the spleen and bone marrow, cytomorphologic analysis, and immunophenotyping (reac- were obtained from cadaveric kidney donors. In addition, two spleens from patients suffering from nonmalignant diseases (autoimmune thrombocytopenia but without clonal B-cell proliferation. hepatic cirrhosis) were studied. Five spleens were obtained from patients with B-cell non-Hodgkin's lymphoma (NHL; 4 with immunocytoma and 1 with mantle cell lymphoma); in all cases, splenectomy was performed for diagnostic purpose. Blood cells from patients with chronic lymphocytic leukemia (CLL; n = 9), from patients with prolymphocytic leukemia (PLL; n = 2), and from I 1 healthy blood donors served as controls. Mononuclear light-density cells were isolated from the spleen by gentle disruption, washing. and Ficoll-Isopaque (1.077 g/mL) density gradient centrifugation. In most cases, the cells were cryopreserved in liquid nitrogen in 10% dimethylsulfoxide until further study. Purified 
TCR y -PCR
Fifty thousand cells were lysed using 0.034 mmol/L sodium dodecy1 sulfate (SDS), 2.5 mmol/L MgCI,, 10 mmol/L Tris/HCI (pH 7 . 3 , and 0.1 mg proteinase K in a final volume of 10 p L for 4 hours at 37°C followed by enzyme inactivation for IO minutes at 85°C. Five microliters of cell lysate derived from a minimum of at least 25,000 cells was amplified by PCR with the primers as described by Taylor et all2 using primer C20/10 (complementary to an identical 21-bp segment in the Jy1.3 and Jy2.3 gene: S'CCCTCTATTACCT-TGGAAATG 3'), and primer T20/10 (identical to a 21-bp sequence within the V y l , Vy2, Vy3, Vy4, Vy5, VySP, and Vy8 genes; 1-bp mismatch with the Vy7 gene; 4-bp mismatch with the Vy6 gene: S'TCTTCCAACTTGGAAGGGAGA 3'). Amplification was performed using a mixture of 30 p L containing 50 mmol/L KCI, I O mmol/L TrisHCl (pH 8.4), 1.5 mmol/L MgCI2, 1 mg/mL bovine serum albumin (BSA), 15 pmol primers, 10 pmol/L dNTP, 0.75 U AmpliTaq DNA polymerase (Perkin Elmer, Roche, Branchburg, NJ), and 22.2 pmol/L [a"P]-dCTP (3,000 Ci/mmol/L; Amersham, Buckinghamshire, UK). The amplification was performed in a Hybaid OmniGene (Biozym, Landgraaf, The Netherlands) for 35 cycles under the following conditions: denaturation at 94°C for I minute, annealing at 56°C for 2 minutes, and extension at 72°C for 3 minutes. The products were digested by Ninfl; the digested and undigested samples were loaded after denaturation for 5 minutes at 95°C in a solution containing (final concentrations in 8 pL) 4 pL PCR product, 20 mmol/L NaOH, 0.2 mmol/L EDTA, 0,025% xylene cyanol, and 0.025% bromophenol blue; put on ice for 5 minutes; and separated on a 8% denaturing PAGE (dPAGE) gel containing 7 mol/L urea and run for 3 hours and 30 minutes. Exposure took place overnight at room temperature. The PCR products were also analyzed under single-strand conformation polymorphism (SSCP) conditions to confirm the presence of clonal bands. To this end, the denatured samples were allowed to form interstrand conformations and fractionated on gels that consisted of 6% polyacrylamide, 90 m m o K Trk/ HCI, pH 8.0, 90 mmol/L boric acid, and 2 mmol/L EDTA.
TCRBV-PCR
Total RNA was isolated by the guanidium isothiocyanate method, as described,'' or with Trizol (GIBCO, BRL, Gaithersburg, MD) The sequences of BV1-23 and CB were derived from Struyk et all6 and Hawes et al,'5 except for the BV6 primer, which has been published by Raaphorst et al/5 and BV12, BV13, BV16, BV21. and the CB primers, which were designed by us. The new nomenclature is used; the previous BV17 is now called BV19 and vice versa. 26 according to the manufacturer's procedure. cDNA was prepared from samples of 2 pg RNA each (derived from at least 2 x IO" T cells) using Moloney's murine leukemia virus (M-MLV) BRL reverse transcriptase (GIBCO, BRL) for 60 minutes at 3?T, as deOne-fiftieth of each cDNA reaction was individually amplified using a TCRBV subfamily-specific primer and a C p primer. Most of the primers have been described previously'','' (Table l). Expression of BV20 was excluded from quantification." Each 50-pL PCR reaction contained cDNA in IO mmol/L TrisHCI, pH 8.4, SO mmol/L KCI, 1 .5 mmol/L MgCI,, 20 pg/ mL BSA, 20 pmol of a TCRBV subfamily-specific primer and the C primer, SO pmoV L dNTPs, 20 pmollL [a-"P]dCTP (3,000 Ci/mmol/L; Amersham), and 1.25 U Taq DNA polymerase. The amplification was started with a denaturation step of 4 minutes at 94°C followed by 25 to 30 cycles, with each cycle consisting of I minute at 94°C 55T, and 72°C. The number of V-Cg amplification cycles required for the individual cDNA samples was first determined by amplifying the constant (C) region of the TCRO cDNA for 20 to 30 cycles and visualization on a ethidium bromide-stained agarose gel. The cycle number at which the constant region amplicons were clearly visible was chosen for amplifying the TCRP repertoire. Clonality within each subfamily was determined by dPAGE and SSCP analysis. After electrophoresis, amplified DNAs were visualized by autoradiography and analyzed using a phosphor imager (see below).
Scanning oj' TCRy and cDNA-TCRP Products
In addition to visual analysis, the dPAGE and SSCP gels were exposed to a Storage Phosphor Screen, secured with a Phosphor Imager 455 SI, and analyzed by ImageQuant NT software (all from Molecular Dynamics, Sunnyvale, CA).
RESULTS
TCR-y Rearrangements
Control experiments. To establish the sensitivity of the TCRy-PCR technique, two clonal T-cell lines were used in Clonal excess:
+ --mixing experiments. Cells from the cell line Jurkat or the JB 1 -B 1 clone were mixed with normal peripheral blood cells and with a T-cell-depleted hairy cell spleen suspension at ratios ranging from 100% cell lines to 1%. Subsequently, the cell mixtures were lysed, PCR-amplified, digested with HinfI, and run on a dPAGE gel. On a background of normal blood cells. S% to 10% clonal T cells could be detected. On purified hairy cells, less than S% clonal T cells could be detected. No rearranged TCRy DNA products could be amplified from purified hairy cell suspensions (n = 4).
T cells purified by cell sorting using anti-CD3 MoAbs from IS of 25 patients showed clonal excess, with S patients exhibiting very strong bands. In I 1 patients we were able to compare the TCRy patterns from blood and splenic T cells (Fig 1 and Table 2 ). There was no correlation for the occurrence of clonal excess between the two compartments. Only 1 patient showed identical patterns in both the splenic and blood T cells. To assess if certain T-cell subsets were responsible for the clonal excess, T cells from 12 samples ( 1 1 spleens and 1 blood sample) from which sufficient material was available were sorted into CD3'CD4' and CD3TD4-or CD3'CD8' and CD3TD8-fractions. In 2 patients the CD3'y/6' subset was also analyzed. Results are HCL. shown in Table 3 . The incidence of clonal excess was higher in the sorted subsets (n = 7) than in unseparated CD3' Tcell populations (n = 4). In 7 of I I patients, oligoclonal bands in a polyclonal background were seen, mainly in the CD8' but also in the CD4' or CD3'yIS' subset. In I case (patient Mu), a strong band was also present in a CD4-and CD8-subset (Fig 2) . Further analysis yielded a doublenegative T-cell population that expressed CD3, TCRaID, and CD2, but lacked CD4, CD8, and TCRyI6.
To assess the reproducibility of the results, 1 1 HCL spleen samples were sorted and tested on two to five separate occasions. In all cases, the same oligoclonal bands reappeared.
Circulating T cells from I 1 patients with CLL or PLL showed oligoclonal bands in 3 cases with CLL and in 1 case with PLL. In 2 of S NHL spleens (both immunocytoma), oligoclonal bands were seen.
In 1 of 7 normal spleens (derived from a kidney donor), one clonal band was found, with the remaining 6 cases showing a polyclonal TCRy pattern. In 2 of I I healthy blood donors, oligoclonal bands were observed.
Otker R-cell mnlignnricies.
Nonmrrlignant controls.
TCR-p Renrrnngernerits
The CDR3 length and conformation from 22 different TCRBV subfamilies were analyzed on cDNA obtained from T cells from 6 patients with HCL, from 2 normal spleens, and from 6 healthy blood donors.
In all patients tested, the CDR3 lengths analyzed on a dPAGE gel disclosed oligoclonal and polyclonal (ie, regular ladder patterns) configurations for the individual subfamilies. Markedly abnormal patterns were found, with clonal bands in many different BV subfamilies (Table 4 and Fig 3) . In addition, several gaps in the T-cell repertoire were present, with BV families missing or showing abnormal weak signals in comparison with normal controls. The presence of the bands within all subfamilies was verified by the
HCL.
For Phosphor Imager. SSCP gel analysis of the T-cell repertoire confirmed the clonal excess patterns seen on the dPAGE gels (data not shown). In all cases with clonal excess as IFN-a was started because of progressive granulocytopenia and thrombocytopenia. This patient never suffered from infections. All blood-derived samples showed identical abnordetermined by the TCRy-PCR, clonal excess was also observed at the level of TCR-fl rearrangements. In addition, this technique yielded oligoclonal T-cell populations in additional cases not detected by the TCRy-PCR. Two HCL patients were tested on several occasions. From patient Hof we analyzed purified T cells from the spleen, from blood at the time of splenectomy, and from blood 2, 5, and 7 months after splenectomy. The last sample was taken directly before CD3+ CD3+ total 4+ 4-8+ 8-W malities with a tendency to become more pronounced during progression of the disease (Fig 4) . Some of the oligoclonal bands in the blood could also be recognized in the spleen (Fig 4) . Patient Hoo was analyzed twice, ie, 14 months after splenectomy (blood sample) and 25 months after splenectomy (blood and bone marrow sample). Although the blood counts clearly showed HCL activity, no anti-HCL therapy was initiated during this period and he did not suffer from infections. A comparison of the TCRBV profile also showed a complete similarity between these three samples assessed (Fig 5) . The scanning patterns measured by the Phosphor Imager confirmed the similarity of all TCRBV subfamilies in both patients during the follow-up (Figs 4 and 5) .
KLUIN-NELEMANS ET AL Table 3. TCR-y PCR in Total T-cell Fractions and in FACS-Sorted T-cell Subsets
Two normal spleens and four normal blood samples were tested. One clonal band was found in 
DISCUSSION
Oligoclonal T-cell populations in HCL patients were analyzed using two methods. First, we observed in more than half of the patients oligoclonal T-cell populations when a TCRy-PCR technique was applied. This method has a sensitivity of detection of a minimum of 5% clonal T cells among a polyclonal T-cell background. This might explain why more clonal excess bands were found when we separated the T cells into CD4, CD8, and TCRyIG fractions. The clonal excess was predominantly seen in the CD8' fractions, but were also found in the CD4', TyIG', and double negative T-cell suspensions (TaIfl+CD4-CD8-). In contrast, we did not observe gross abnormalities in the normal controls tested. However, Hingorani et allx reported a higher incidence of clonal predominance within circulating CD8TD45RO' T cells in 5 of IO adult normal human subjects. This discrep- In half of the HCL patients in whom we could compare blood-derived and splenic T cells, discrepancies were found without a predominance for T-cell oligoclonality in either compartment. In an earlier study, we have shown that, in HCL, splenic T cells largely differ from circulating T cells as far as ratios for CD4 and CD8 and the expression of CD45RO within these subsets are concerned: The fact that T-cell oligoclonality was not restricted to one of these compartments suggests that the direct contact with hairy cells is not required for these T-cell abnormalities.
A disadvantage of applying an assay for oligoclonality at the genomic level (the TCRy-PCR) is the risk of false-positive results due to TCR rearrangements by the tumor cells themselves. Although variant HCL cases with clonally rearranged TCRy and TCRP genes have been de~cribed,'~.*~ we and others did not observe this in normal HCL?' Recently, clonal T-cell populations were found in other B-cell malignancies, eg, in CLL9s22 and multiple myeloma? Wen et a19 applied a standard Southern technique using a TCRP probe and found clonal rearranged bands in 3 of 12 CLL patients and in 1 of 8 multiple myeloma patients. Remarkably, only patients with early disease (stage 0 CLL and smoldering myeloma) harbored circulating clonal T cells. Because the T cells were positively selected and multiple clones were seen in several cases, cross-lineage rearrangements in the tumor cells were considered unlikely. Farace et alZZ confirmed the presence of multiple T-cell clones in almost all CLL patients (all of them with early disease) using a PCR technique amplifying AV and BV subfamilies. They succeeded in the expansion of a BV19+ T-cell clone that specifically recognized autologous CLL cells, which supports the view that oligoclonal T cells might play a role in anti-tumor reactivity.
When we studied the TCRBV repertoire at the mRNA level, impressive abnormal patterns were seen in all HCL patients tested. Apparently, detailed analysis of BV subfamilies detects more abnormalities than when a TCRy-PCR is /" i Although it is difficult to compare the two procedures, the improved sensitivity of TCRBV-PCR analysis may be largely due to dividing the complete repertoire into 22 subsets. This would indicate that the TCRy-PCR data presented in Table 2 are in fact an overrepresentation of polyclonality in HCL patients if all patients had been tested by TCRBV-PCR as well. Not only were clonal T-cell populations observed in all cases tested in several BV subfamilies each, but also large gaps were seen, with many subfamilies missing. The spleens and blood samples were collected in the absence of manifest infections. The strongest argument that our findings are not coincidental but intrinsically related to the disease is the fact that 2 patients with active HCL without infections or treatment could be observed over time. We found complete identical abnormal patterns in the TCRBV subfamilies in samples taken 1 year from each other, with the same clonal excess bands and gaps in certain BV families.
Clonal involvement of T cells in HCL might explain many observations, such as hyperactive T-cell responses in v i t r~~. '~ and the presence of activated T cells in HCL spleens: which suggest an attempt for immune surveillance function by these cells. The skewed TCRBV repertoire can also contribute to the severe immune deficiency found in many patients with HCL.'~' The large gaps in many BV families are a new finding and have not been found in patients with other Bcell malignancies. Although superantigens can induce expansion of BV specific T cells followed by deletion of specific BV families,% thus far, no viral or bacterial antigen has been found that may play a role in HCL pathogenesis. Further studies including the expansion of the T-cell clones found are necessary to get more insight in the inhibitory and stimulatory factors and potential antigens responsible for this phenomenon in HCL.
CDl lalleukocyte function antigen-1 and CD54/intercellular adhesion molecule-1 on hairy cell leukemia cells is accompanied by enhanced susceptibility to T-cell but not lymphokine-activated killercell cytotoxicity. Blood 80478, 1992 
